AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36368151 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgically treated ACL injury
Number of subjects: 125
Study 36368176 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II diabetes mellitus (T2DM)
Number of subjects: 2002
Study 36368176 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus (no-DM)
Number of subjects: 2002
Study 36368480 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-1 (Recovering Together intervention)
Number of subjects: 194
Study 36368480 — intervention group
Group type: COMPARATOR
Intervention: RT-2 (Health education control)
Number of subjects: 194
Study 36368697 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel venous cannula as part of the EXCOR® VAD for subpulmonary support
Number of subjects: 20
Study 36368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prerelese methadone (n=64)
Number of subjects: 291
Study 36368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incarceration alcohol use
Number of subjects: 291
Study 36368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 291
Study 36368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CD4 count
Number of subjects: 291
Study 36369028 — intervention group
Group type: EXPERIMENTAL
Intervention: TAAR1 agonists
Number of subjects: 0
Study 36369156 — intervention group
Group type: EXPERIMENTAL
Intervention: Home handheld spirometry
Number of subjects: 0
Study 36369278 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural heart disease (SHD) patients
Number of subjects: 152
Study 36369278 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial presence of SARS-CoV-2
Number of subjects: 152
Study 36369278 — intervention group
Group type: COMPARATOR
Intervention: Myocardial ACE2 expression
Number of subjects: 152
Study 36369278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical course of patients with cardiac SARS-CoV-2 manifestation
Number of subjects: 152
Study 36369401 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV PCR on inner ear fluid
Number of subjects: 113
Study 36369507 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth support comprising automated twice-weekly telephone calls with a specialist nurse triaging alerts.
Number of subjects: 0
Study 36369507 — intervention group
Group type: COMPARATOR
Intervention: Standard care without telehealth support (implied control group).
Number of subjects: 0
Study 36369530 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36369729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mama na Mtoto intervention
Number of subjects: 2070
Study 36369848 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-297 20-600 μg single doses
Number of subjects: 82
Study 36369848 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-297 5-90 μg once daily for 14 days
Number of subjects: 82
Study 36369848 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-297 (all doses)
Number of subjects: 82
Study 36369848 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-297 (60 μg MAD)
Number of subjects: 82
Study 36370026 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of well-being
Number of subjects: 719
Study 36370064 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical family (HF) haematopoietic cell transplantation (HCT)
Number of subjects: 101
Study 36370064 — intervention group
Group type: COMPARATOR
Intervention: Matched sibling (MS) haematopoietic cell transplantation (HCT)
Number of subjects: 101
Study 36370064 — intervention group
Group type: COMPARATOR
Intervention: Unrelated donor (UD) haematopoietic cell transplantation (HCT)
Number of subjects: 101
Study 36370220 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal RVFWLS (> -20%)
Number of subjects: 104
Study 36370220 — intervention group
Group type: COMPARATOR
Intervention: Normal RVFWLS (<= -20%)
Number of subjects: 104
Study 36370226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 29
Study 36370233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort), one drop per eye every evening
Number of subjects: 725
Study 36370233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort)
Number of subjects: 725
Study 36370742 — intervention group
Group type: EXPERIMENTAL
Intervention: Olutasidenib monotherapy (150 mg once daily, 150 mg twice per day, 300 mg once daily)
Number of subjects: 78
Study 36370742 — intervention group
Group type: EXPERIMENTAL
Intervention: Olutasidenib in combination with azacitidine (75 mg/m2)
Number of subjects: 78
Study 36370892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed to increase comprehensive smokefree policies in the homes
Number of subjects: 191
Study 36370892 — intervention group
Group type: COMPARATOR
Intervention: No ban on smoked tobacco products
Number of subjects: 191
Study 36370892 — intervention group
Group type: COMPARATOR
Intervention: Partial or complete ban on smoked tobacco products
Number of subjects: 191
Study 36370892 — intervention group
Group type: COMPARATOR
Intervention: Financial security perception
Number of subjects: 191
Study 36370915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminations
Number of subjects: 100
Study 36370915 — intervention group
Group type: EXPERIMENTAL
Intervention: Future interventions
Number of subjects: 100
Study 36371196 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with ARDS
Number of subjects: 100
Study 36371196 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher methylation of 'Apoptotic execution Pathway' genes (ROC1, ZNF789, H1F0) at inclusion
Number of subjects: 100
Study 36371196 — intervention group
Group type: COMPARATOR
Intervention: Comparison of COVID-19 patients to controls at inclusion
Number of subjects: 100
Study 36371222 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hemoglobin A1c level (per 1% increase)
Number of subjects: 402
Study 36371222 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hemoglobin A1c level
Number of subjects: 402
Study 36371222 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal predictive cut-off value of hemoglobin A1c level for RPP
Number of subjects: 402
Study 36371226 — intervention group
Group type: EXPERIMENTAL
Intervention: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly, 100 radioiodinated omburtamab injections at a recommended phase 2 dose of 1850 MBq/injection.
Number of subjects: 38
Study 36371226 — intervention group
Group type: EXPERIMENTAL
Intervention: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly.
Number of subjects: 38
Study 36371330 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Number of subjects: 15
Study 36371408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg CoVLP+AS03
Number of subjects: 0
Study 36371488 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous closure of iASD
Number of subjects: 36
Study 36371488 — intervention group
Group type: COMPARATOR
Intervention: Residual shunt group
Number of subjects: 36
Study 36371986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure for 120 minutes
Number of subjects: 0
Study 36371986 — intervention group
Group type: COMPARATOR
Intervention: Blocking adipose triglyceride lipase (ATGL) with Atglistatin in mice
Number of subjects: 0
Study 36372082 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-associated hospitalisations
Number of subjects: 9154
Study 36372082 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric intensive care unit admissions
Number of subjects: 9154
Study 36372082 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance cohort for RSV infection
Number of subjects: 9154
Study 36372245 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-001 (1000 mg BID)
Number of subjects: 675
Study 36372245 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-001 (1500 mg BID)
Number of subjects: 675
Study 36372245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study 36372251 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels (measured by wrist-mounted triaxial accelerometer)
Number of subjects: 93
Study 36372251 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults (age-matched NHANES participants)
Number of subjects: 93
Study 36372251 — intervention group
Group type: COMPARATOR
Intervention: Adults with chronic, stable HF (age-matched NHANES participants)
Number of subjects: 93
Study 36372287 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hyperaemic Pd/Pa
Number of subjects: 2141
Study 36372287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemic pressure ratio (FFR)
Number of subjects: 2141
Study 36372287 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of FFR and non-hyperaemic Pd/Pa
Number of subjects: 2141
Study 36372287 — intervention group
Group type: COMPARATOR
Intervention: Deferred revascularization in vessels with abnormal pressure ratios
Number of subjects: 2141
Study 36372356 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC infusion on the day of leukocyte recovery to 1000 cells/μL (engraftment, day E0)
Number of subjects: 0
Study 36372356 — intervention group
Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis
Number of subjects: 0
Study 36372356 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC infusion on day E0
Number of subjects: 0
Study 36372442 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsavir (active moiety)
Number of subjects: 26
Study 36372442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir co-administration with hormone therapy
Number of subjects: 26
Study 36372442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir
Number of subjects: 26
Study 36372442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir with combined oral contraceptives (COCs)
Number of subjects: 26
Study 36372442 — intervention group
Group type: EXPERIMENTAL
Intervention: Other oestrogen-based therapies with fostemsavir
Number of subjects: 26
Study 36372851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia (measured by bioelectrical impedance vector analysis)
Number of subjects: 186
Study 36372851 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 186
Study 36372851 — intervention group
Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 186
Study 36372851 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 186
Study 36372873 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF ctDNA positivity at baseline
Number of subjects: 92
Study 36372873 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 50% reductions in CSF ctDNA concentrations after 8 weeks of treatment
Number of subjects: 92
Study 36372873 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 50% reductions in plasma ctDNA concentrations
Number of subjects: 92
Study 36372873 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal mutations remaining in more than 80% in CSF after 8 weeks
Number of subjects: 92
Study 36372884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA)
Number of subjects: 20
Study 36373234 — intervention group
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP) in PCOS patients
Number of subjects: 66
Study 36373234 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen concentrations in PCOS patients
Number of subjects: 66
Study 36373234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-hormone-binding globulin in PCOS patients
Number of subjects: 66
Study 36373234 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 66
Study 36373249 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109) in combination with other antiviral agents
Number of subjects: 4
Study 36373249 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109)
Number of subjects: 4
Study 36373403 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity (PA)
Number of subjects: 321
Study 36373403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports/exercise PA
Number of subjects: 321
Study 36373555 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise protocol for neck pain (4 weeks)
Number of subjects: 15
Study 36373868 — intervention group
Group type: EXPERIMENTAL
Intervention: BurstDR™ spinal cord stimulation (SCS)
Number of subjects: 17
Study 36374531 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO mHealth tool intervention (6 PRO text messages a day for 12 months)
Number of subjects: 61
Study 36374531 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers (42 patients)
Number of subjects: 61
Study 36374531 — intervention group
Group type: COMPARATOR
Intervention: Noncompleters (19 patients)
Number of subjects: 61
Study 36374541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelight software
Number of subjects: 8585
Study 36375046 — intervention group
Group type: EXPERIMENTAL
Intervention: LO-CHOP (lenalidomide and obinutuzumab with CHOP)
Number of subjects: 53
Study 36375115 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 139
Study 36375115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Number of subjects: 139
Study 36375120 — intervention group
Group type: EXPERIMENTAL
Intervention: NRX-0492
Number of subjects: 0
Study 36375125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD)
Number of subjects: 606
Study 36375125 — intervention group
Group type: COMPARATOR
Intervention: Nonpalpable spleen
Number of subjects: 606
Study 36375125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 606
Study 36375132 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (CFZ) combined with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE)
Number of subjects: 29
Study 36375174 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotics
Number of subjects: 2769
Study 36375174 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 2769
Study 36375174 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilisers
Number of subjects: 2769
Study 36375343 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative analysis of warning signs in the 24-h period prior to suicide attempt
Number of subjects: 35
Study 36375653 — intervention group
Group type: EXPERIMENTAL
Intervention: N20Amp at 12-24 hours
Number of subjects: 236
Study 36375653 — intervention group
Group type: EXPERIMENTAL
Intervention: N20Amp cutoff at 12-24 hours
Number of subjects: 236
Study 36375653 — intervention group
Group type: EXPERIMENTAL
Intervention: N20Amp sensitivity at 12-24 hours
Number of subjects: 236
Study 36375653 — intervention group
Group type: EXPERIMENTAL
Intervention: N20Amp decrease > 53%
Number of subjects: 236
Study 36375653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of N20Amp decrease and N20Amp < 1.23 µV at 72 h
Number of subjects: 236
Study 36375678 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus Obinutuzumab (VenO)
Number of subjects: 0
Study 36375678 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil plus Obinutuzumab (ClbO)
Number of subjects: 0
Study 36375971 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient parenteral antimicrobial therapy (OPAT)
Number of subjects: 0
Study 36375971 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of physician-side factors
Number of subjects: 0
Study 36375971 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of OPAT patient cohort
Number of subjects: 0
Study 36375981 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin plus docetaxel)
Number of subjects: 0
Study 36375981 — intervention group
Group type: COMPARATOR
Intervention: ECF/ECX chemotherapy (epirubicin, cisplatin plus fluorouracil or capecitabine)
Number of subjects: 0
Study 36375985 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry examination
Number of subjects: 0
Study 36375985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic dysfunction tests
Number of subjects: 0
Study 36375985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve conduction test
Number of subjects: 0
Study 36376099 — intervention group
Group type: EXPERIMENTAL
Intervention: ClotPro® thromboelastometry analyser
Number of subjects: 321
Study 36376109 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function assessment on day 0, day 2, and day 7
Number of subjects: 35
Study 36376109 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic anticoagulation
Number of subjects: 35
Study 36376130 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of edaravone with a meal
Number of subjects: 34
Study 36376130 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of edaravone 8 hours after a high-fat meal
Number of subjects: 34
Study 36376130 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of edaravone 4 hours after a low-fat meal
Number of subjects: 34
Study 36376130 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of edaravone 2 hours after a light meal
Number of subjects: 34
Study 36376130 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of edaravone 1 hour before a high-fat meal
Number of subjects: 34
Study 36376393 — intervention group
Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine at 10 μg
Number of subjects: 72
Study 36376393 — intervention group
Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine at 25 μg
Number of subjects: 72
Study 36376393 — intervention group
Group type: EXPERIMENTAL
Intervention: ChulaCov19 vaccine at 50 μg
Number of subjects: 72
Study 36376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative management
Number of subjects: 69
Study 36376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative management
Number of subjects: 69
Study 36376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative management
Number of subjects: 69
Study 36376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of cases
Number of subjects: 69
Study 36376560 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management and cases
Number of subjects: 69
Study 36376636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (n=2656)
Number of subjects: 5311
Study 36376636 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (n=2655)
Number of subjects: 5311
Study 36376636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination rationale (n=1786)
Number of subjects: 5311
Study 36376636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of benefit rationale (n=1755)
Number of subjects: 5311
Study 36376636 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential for harm rationale (n=1770)
Number of subjects: 5311
Study 36376733 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 μg)
Number of subjects: 593
Study 36376733 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100 μg)
Number of subjects: 593
Study 36376733 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 μg and 100 μg)
Number of subjects: 593
Study 36376733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 36376833 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF rs3025039 CC genotype
Number of subjects: 200
Study 36376833 — intervention group
Group type: EXPERIMENTAL
Intervention: KDR rs2071559 AA genotype
Number of subjects: 200
Study 36376960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported intervention targeting diabetes and medication beliefs, communication, and self-efficacy skills; details on dosage and duration not specified.
Number of subjects: 39
Study 36376960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported intervention; details on dosage and duration not specified.
Number of subjects: 39
Study 36377124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 413
Study 36377504 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0
Study 36377504 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 0
Study 36377504 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-652-3p
Number of subjects: 0
Study 36377504 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-32-5p and miR-339-3p
Number of subjects: 0
Study 36377523 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment
Number of subjects: 180
Study 36378074 — intervention group
Group type: EXPERIMENTAL
Intervention: BA.4/BA.5-adapted mRNA booster vaccine
Number of subjects: 0
Study 36378074 — intervention group
Group type: COMPARATOR
Intervention: BA.1-adapted mRNA vaccine (bivalent format: wild-type + BA.1)
Number of subjects: 0
Study 36378074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent wild-type + BA.4/BA.5 vaccine
Number of subjects: 0
Study 36378074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent wild-type + Omicron BA.4/BA.5 vaccine
Number of subjects: 0
Study 36378267 — intervention group
Group type: EXPERIMENTAL
Intervention: THC and CBD in edible cannabis products
Number of subjects: 0
Study 36378539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Number of subjects: 95
Study 36378539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 36378548 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA737 (500 mg) combined with low-dose gemcitabine (250 mg/m2)
Number of subjects: 143
Study 36378565 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II
Number of subjects: 3976
Study 36378565 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE IV
Number of subjects: 3976
Study 36378565 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS-R
Number of subjects: 3976
Study 36378565 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 3976
Study 36378565 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model performance
Number of subjects: 3976
Study 36378565 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleven models
Number of subjects: 3976